CD1a is a lipid-presenting molecule that is abundantly expressed on Langerhans cells. However, the in vivo role of CD1a has remained unclear, principally because CD1a is lacking in mice. Through the use of mice with transgenic expression of CD1a, we found that the plant-derived lipid urushiol triggered CD1a-dependent skin inflammation driven by CD4 + helper T cells that produced the cytokines IL-17 and IL-22 (T H 17 cells). Human subjects with poison-ivy dermatitis had a similar cytokine signature following CD1a-mediated recognition of urushiol. Among various urushiol congeners, we identified diunsaturated pentadecylcatechol (C15:2) as the dominant antigen for CD1a-restricted T cells. We determined the crystal structure of the CD1a-urushiol (C15:2) complex, demonstrating the molecular basis of urushiol interaction with the antigen-binding cleft of CD1a. In a mouse model and in patients with psoriasis, CD1a amplified inflammatory responses that were mediated by T H 17 cells that reacted to self lipid antigens. Treatment with blocking antibodies to CD1a alleviated skin inflammation. Thus, we propose CD1a as a potential therapeutic target in inflammatory skin diseases.
The family of CD1 molecules consists of group 1 CD1 proteins (CD1a, CD1b, CD1c and CD1e) and group 2 CD1 proteins (CD1d) 1 . In contrast to major histocompatibility complex proteins that present peptides, CD1 molecules present lipid antigens to T lymphocytes 1, 2 . For example, the CD1d molecule presents α-anomeric glycosphingolipids to invariant natural killer T cells 3 , whereas CD1a-c molecules have been shown to present lipids and lipopeptides from mycobacteria to a diverse T cell repertoire 4 . Notably, CD1a can display a broad spectrum of exogenous lipid antigens derived from pollen 5 or bacteria [6] [7] [8] . In addition, CD1a also presents self lipid antigens from host origin [9] [10] [11] [12] [13] [14] [15] , such as triacylglycerol, squalene, wax ester and fatty acid, which are enriched in the skin epidermis 11 .
Abundant expression of CD1a is a hallmark of Langerhans cells (LCs) in the skin. LCs originate from yolk-sac-derived fetal liver progenitors 16, 17 , require IL-34 for development 18, 19 and constitute the principal dendritic cell (DC) subset in the epidermis 20, 21 . In addition, the dermis harbors dermal as well as langerin-positive DCs. The three DC types in the skin fulfill different functions in antigen presentation; for example, langerin-positive dermal DCs are important for cross-priming of CD8 + T cells, whereas LCs 'preferentially' induce T H 17 cells 22, 23 .
The intricate immune system of the skin is critically involved in responses to extrinsic insults such as allergens 24 , as well as in autoimmune diseases, such as psoriasis 25, 26 . Contact dermatitis is a common skin disease caused by exposure to small organic or inorganic molecules 24 . During the sensitization phase, allergen-specific T lymphocytes are generated that mediate skin inflammation following challenge with the same antigen 24 . The sap compound urushiol found in the plants of the genus Toxicodendron, such as poison oak, poison sumac and poison ivy 27 , can trigger severe inflammation, and urushiol-specific T cells have been linked to this process in the human system [28] [29] [30] . Psoriasis is a chronically relapsing, T cell-mediated inflammatory skin disease with a prevalence of 2-3% worldwide 25, 26 . The disease is characterized by epidermal thickening (acanthosis), which leads to itchy and scaling macroscopic plaques 25, 26 . It is well known that the cytokines IL-17 and IL-22 are crucial for the development of psoriasis 26 . Although psoriasis is considered an autoimmune disease, the identity of the antigens recognized have remained elusive 26 .
Given that LCs express predominantly CD1a and reside in the epidermis, which is readily accessible to foreign as well as self-lipid antigens, LCs and CD1a-restricted T cells are prime candidates for regulating skin immunity. However, given that CD1a is expressed in humans but lacking in mice 1 , the in vivo functions of CD1a on LCs have not been addressed and have remained unclear.
Here we found that LCs expressing CD1a were vital for skin inflammation in vivo. To investigate the role of CD1a on LCs in the induction of inflammatory skin diseases, we used mice with transgenic expression of human CD1a (CD1a-tg mice) and found that CD1a drove the 1 1 6 0 VOLUME 17 NUMBER 10 OCTOBER 2016 nature immunology A r t i c l e s pathogenesis of poison-ivy dermatitis and psoriasis. Furthermore, we found that CD1a-mediated skin inflammation was abrogated by CD1a-blocking antibodies, which highlights CD1a as a target for treatment of inflammatory skin diseases.
RESULTS
CD1a promotes skin inflammation in response to poison ivy CD1a presents lipid antigens with defined alkyl chain length to activate T cells 9, 11, 15 . On the basis of its lipophilic nature and size, we hypothesized that urushiol might represent a ligand displayed by CD1a to cause inflammation. To investigate this, we sensitized and challenged CD1a-tg and wild-type mice with urushiol applied to the ear skin. Ear thickness, a first indicator of inflammation, was markedly increased in the presence of CD1a (Fig. 1a) . Histological analysis revealed a pronounced cellular infiltrate, especially in the dermis of urushioltreated CD1a-tg mice (Fig. 1b) . We analyzed the skin-infiltrating cells by flow cytometry and found a significant increase in inflammatory granulocytes and macrophages in CD1a-tg mice ( Fig. 1c,d) . Dermal T lymphocytes bearing a γδ T cell antigen receptor (TCR) expanded in number to the same extent in both mouse strains ( Fig. 1e,f) . In contrast, the presence of CD1a promoted the specific amplification in the number of CD4 + αβ T cells, whereas the participation of CD8 + T cells proved to be negligible ( Fig. 1e,f) . Investigating the functional cytokine responses of these lymphocytes, we found that the abundance of CD4 + helper T cells producing IL-17 and IL-22 (T H 17 cells) was markedly increased in the CD1a-tg mouse model ( Fig. 1g,h) . Thus, CD1a promotes T H 17 cell-mediated skin inflammation in response to poison-ivy-derived urushiol.
Next we investigated whether our findings in the mouse model were relevant to humans. For this purpose, we tested CD45RO + memory T cells from the blood of human subjects (n = 6) who had experienced moderate-to-severe poison-ivy rash in the past 6 months. Antigen-presenting cells (K562 cells) transfected to express CD1a or parental control cells were pulsed with urushiol or vehicle before culture together with T lymphocytes from poison-ivy-affected or healthy donors. Subsequent analysis of T cell activation revealed increased production of IL-17 and IL-22 by T cells from poison-ivy-affected donors that responded specifically to urushiol in a CD1a-dependent manner ( Fig. 2a,b) . Thus, in the context of our data in the CD1atransgenic system, human subjects with poison-ivy dermatitis showed a similar inflammatory cytokine signature following CD1a-mediated recognition of urushiol. npg Adaptive immunity to urushiol differs from a hapten response We then determined whether the immune response to urushiol was based on adaptive immunity or innate mechanisms locally at work in the skin. In the absence of initial sensitization, CD1a-tg mice that were challenged only with urushiol failed to develop increased skin inflammation, as indicated by skin infiltration and IL-17-producing CD4 + T cells ( Fig. 3a,b) . Although urushiol had a direct effect on innate inflammation, upregulation of inflammatory mediators, such as IL-1β and TNF, was similar in CD1a-tg mice and wild-type mice ( Supplementary Fig. 1 ). Thus, CD1a-dependent immunity to urushiol involved antigen-specific T cell priming. To exclude the possibility of a generally increased susceptibility of CD1a-tg mice to antigenic stimulation, we assessed the immune response to the classical hapten dinitrofluorobenzene (DNFB) 24 . To our surprise, ear swelling was less in the CD1a-tg mouse model than in wild-type mice ( Supplementary  Fig. 2a ). In addition to their reduced influx of inflammatory granulocytes, CD1a-tg mice generated considerably fewer CD8 + T cells in response to DNFB and accordingly showed reduced production of IFN-γ ( Supplementary Fig. 2b,c) . Thus, the CD1a-tg mice did not have a generally enhanced susceptibility to stimulation with hapten.
CD1a on LCs is important for T H 17 cell-mediated dermatitis
Using confocal microscopy of epidermal sheets, we examined the LC network in the epidermis as well as their exclusive CD1a expression in the CD1a-tg mouse model ( Fig. 4a) . Moreover, we analyzed all skin DCs by flow cytometry and found that the CD1a + population overlapped with the population of langerin-expressing LCs (Fig. 4b) .
Subsequently, we monitored CD1a expression on skin DCs during the immune response to urushiol. In vehicle-treated control skin, the composition of skin DCs proved to be similar in CD1a-tg mice and wild-type mice ( Fig. 4c) , indicative of normal homeostasis.
In the inflamed ear skin, we observed a massive influx of inflammatory, CD1a-negative DCs (Fig. 4c) . In contrast, epidermal LCs were the main population that specifically expressed CD1a during poison-ivy-induced dermatitis ( Fig. 4c) . Given that exclusive expression pattern, we next sought to inhibit CD1a function on LCs. For this purpose, we treated mice during the sensitization phase with CD1a-blocking antibodies. Notably, treatment with antibody to CD1a (anti-CD1a) reduced ear swelling in CD1a-tg mice to the levels in wild-type mice, in contrast to results obtained by the administration of isotype-matched control antibody ( Fig. 4d) . Accordingly, infiltration of inflammatory granulocytes and IL-17-producing CD4 + T cells was equally abrogated by anti-CD1a treatment ( Fig. 4e,f) . Of note, the application of anti-CD1a has no depleting effect but instead blocks CD1a's function on the surface of LCs. In this context, we found downregulation of CD1a on skin LCs following treatment with anti-CD1a, although diminishment of CD1a appeared to be incomplete, a Veh Uru Veh Mock CD1a APC:
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Poison ivy Healthy IL-22 Figure 2 Human subjects with poison-ivy dermatitis show urushiolspecific T cell responses mediated by CD1a. (a) Flow cytometry of CD45RO + memory T cells sorted from the peripheral blood of donors (n = 6) who experienced contact dermatitis caused by poison ivy in the previous 6 months or that of healthy control donors (n = 6) (left margin) and then cultured for 3 d together with mock-transfected K562 cells (Mock) or K562 cells transfected to express CD1a (top), loaded with vehicle or urushiol (C15:2) (above plots). Numbers in quadrants indicate percent IL-17 + A r t i c l e s possibly as a result of limited accessibility of the epidermis for systemically administered antibodies ( Fig. 4g) . However, in skin-draining lymph nodes, treatment with anti-CD1a led to full downregulation of CD1a on migrating LCs (Fig. 4g) . Together our data indicated that CD1a-expressing LCs were essential for the generation of T H 17 cells and skin inflammation.
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Urushiol (C15:2) is an antigen for CD1a-restricted T cells Given that poison ivy induced strong CD1a-mediated inflammation, we next investigated whether urushiol is a bona fide antigen presented by CD1a. For this purpose, we loaded plate-bound recombinant human CD1a molecules with urushiol before incubating them with CD4 + T cells isolated from urushiol-immunized mice. In sharp contrast to lymphocytes from wild-type mice, only CD4 + T cells isolated from CD1a-tg mice produced IL-17 in response to urushiol-loaded CD1a molecules (Fig. 5a) . This system was free of antigen-presenting cells and thus demonstrated the direct presentation of urushiol by CD1a. Given that natural urushiol contains a mixture of different pentadecylcatechols, we subsequently determined which congener was responsible for its antigenic properties. Using the same recombinant CD1a system and synthetically generated urushiol congeners, we found that pentadecylcatechol with two unsaturations (C15:2) was the dominant immunogen for the CD1a-mediated activation of T cells (Fig. 5b) . We also observed that C15:2 mediated the observed effects of increased skin inflammation in CD1a-tg mice (Fig. 5c) . To mimic urushiol presentation in its natural habitat, we isolated LCs from ear skin of immunized CD1a-tg animals before pulsing them with C15:2 and culturing them together with CD4 + T cells from draining lymph
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9.9 ± 0.8 nodes. LCs triggered a strong T H 17 cell response following presentation of C15:2 in a strictly CD1a-specific manner, as anti-CD1a fully abolished T cell activation ( Fig. 5d) . Of note, a substantial degree of autoreactive, CD1a-restricted T cell stimulation was observed with unpulsed LCs (Fig. 5d) .
A classic feature of adaptive immunity is the clonal expansion of antigen-specific T cells, characterized by a usage of a certain TCR by amplified cells. Thus, we investigated the TCR repertoire of the immune response to urushiol. Notably, T cells in inflamed skin of CD1a-tg mice exhibited a substantial increase in usage of TCRs expressing β-chain variable region 2 (V β 2) or V β 4 (Supplementary Fig. 3a) , suggestive of clonal expansion under antigenic selection pressure. The V β 2 + and V β 4 + T cell clones in CD1a-tg mice produced larger amounts of IL-17 than did those in wild-type mice ( Supplementary  Fig. 3b) . Moreover, amplification of V β 2 + and V β 4 + T cells was substantially hampered when CD1a function was blocked by treatment with anti-CD1a (Supplementary Fig. 3c ). These changes in TCR repertoire were specific for T cells during skin inflammation, as normal control skin showed no difference between wild-type mice and CD1a-tg mice in their TCR usage (Supplementary Fig. 3d ). In addition, the CD1a-tg mouse model revealed no alterations in the TCR repertoire in the thymus (Supplementary Fig. 3e) , which excluded the possibility of differential thymic selection. Together our results on functional presentation and TCR repertoire suggested urushiol as an antigen for CD1a-restricted T cells.
Crystal structure of the CD1a-urushiol (C15:2) complex We sought to obtain molecular insight into the mechanism by which CD1a presented urushiol. To establish this, we recombinantly expressed the CD1a molecule in mammalian cells and loaded it with the urushiol ligand (C15:2) in vitro. As CD1a expressed in mammalian cells presents a heterogeneous array of self lipid ligands in its antigenbinding cleft, the endogenous lipids were initially displaced by the ganglioside GD 3 . Subsequently, GD 3 bound to CD1a was specifically displaced by urushiol, with the CD1a-urushiol complex being purified from CD1a-GD 3 via anion-exchange chromatography. Next, we crystallized and determined the structure of the CD1a-urushiol binary complex to 1.9-Å resolution ( Fig. 6a and Supplementary Table 1 ). Unbiased electron density was visible for the urushiol ligand, with the ligand clearly being bound in a non-covalent way in the CD1a antigenbinding cleft (Supplementary Fig. 4a,b) . Mass spectrometry confirmed the presence of urushiol (mass/charge ratio (m/z), 317.24) both in the purified recombinant CD1a sample loaded with urushiol and in crystals of the CD1a-urushiol binary complex (Fig. 6b,c) . Accordingly, our data indicated that CD1a directly presents urushiol.
The antigen-binding cleft of CD1a comprises the A′-and F′-pockets; the A′-pocket is considered to function as a molecular ruler, favoring acyl chains between C 18 and C 23 in length 15 . For example, in the structure of the CD1a-lysophosphatidylcholine complex, the acyl chain winds round the A′-pocket, whereas the polar head group is positioned at the junction of A′-and F′-portals 9 . As anticipated, we found A r t i c l e s that the urushiol antigen was positioned deep in the CD1a-binding cleft, spanning the A′-pocket to the F′-pocket (Fig. 7a) . However, the catechol head group and acyl chain were positioned toward the A′-pocket and F′-pocket, respectively, in the reverse direction to what might have been anticipated on the basis of previous CD1a-antigen structures (Fig. 6a) . Here, the urushiol antigen interacted mainly via van der Waals contacts with residues of the α1-helix of CD1a ( Fig. 6a  and Supplementary Table 2) . The aromatic catechol headgroup of the antigen was positioned in the A′-pocket and was stacked against Phe70, whereas the 3′-hydroxyl formed a hydrogen bond with the main-chain carbonyl of Leu66. The C15:2 aliphatic tail of urushiol sat over the hydrophobic platform formed by Val12, Trp14, Val98 and Leu116 (Fig. 6a) . 80% of the urushiol molecule was buried in the CD1a cleft (with a buried surface area of ~495 Å 2 ). Thus, CD1a presented the urushiol antigen with 20% of its molecular surface potentially exposed at the F′-portal for direct TCR contact (Fig. 7b) .
CD1a facilitates T H 17 cell-driven psoriatic skin inflammation
Given the substantial IL-17 production by CD1a-autoreactive T cells (Fig. 5d ) and the prominent function of IL-17 in psoriasis 25, 26 , we hypothesized that CD1a might be important for psoriatic inflammation. We investigated CD1a-tg mice in a well-established model of psoriasiform inflammation in which the small-molecule compound imiquimod is administered to the skin 31 . We observed greater cellular infiltration of the skin, more epidermal hyperplasia and greater ear swelling in CD1a-tg mice than in wild-type mice (Fig. 8a,b) . Next, we aimed to treat psoriasiform inflammation with CD1a-blocking antibodies. Treatment with anti-CD1a significantly reduced skin inflammation in CD1a-tg mice (Fig. 8c) . This therapeutic effect was mirrored by a reduction in the abundance of inflammatory granulocytes and CD4 + T cells that produced IL-17A, IL-17F and IL-22 (Fig. 8d,e) .
Taking into account the fact that we did not challenge CD1a-tg mice with exogenous lipids in the psoriasis model noted above, we hypothesized that during the inflammatory process, self lipid antigens are released to facilitate CD1a-mediated T cell responses and skin inflammation. To investigate this, we isolated T cells from the skin-draining npg lymph nodes of imiquimod-treated mice and then incubated the cells with plate-bound CD1a molecules loaded with self lipids that have been reported to be skin antigens 11 . T cells from CD1a-tg mice specifically responded to CD1a-restricted self lipid presentation, with pronounced recognition of fatty acids, squalene, wax esters and triacylglycerol ( Fig. 8f) . Of note, we did not detect any meaningful production of IL-17 in untreated CD1a-tg mice (Fig. 8f) , which emphasized the proposal that in the absence of inflammation, there was a complete lack of presentation and recognition of self lipid antigen. Ultimately, we wanted to translate our findings in the psoriasis-like model to the human system. For this purpose, we studied a cohort of patients with moderate-to-severe plaque psoriasis and healthy donors, measuring CD1a-restricted T cell activation. Accordingly, we stimulated CD45RO + memory T cells from the blood of patients with psoriasis (n = 6) or healthy donors (n = 6) with autologous monocytederived DCs in the presence or absence of anti-CD1a before measuring cytokine responses. Notably, we observed more production of IL-17 and IL-22 protein in T cells from patients with psoriasis than in those from healthy donors (Fig. 8g) . Moreover, the inflammatory cytokine response in patients with psoriasis was significantly blocked by anti-CD1a treatment (Fig. 8g) . Collectively, our mouse model for psoriasis and human studies have presented strong evidence that CD1a drives psoriatic skin inflammation and that targeting CD1a can abrogate inflammatory skin disease.
DISCUSSION
Using mice with transgenic expression of human CD1a, we found a vital role for CD1a in skin inflammation in vivo. Given that wild-type mice lack CD1a expression, previous reports investigating LC functions in the murine system neglected the integral role of CD1a. Our CD1a-tg mouse model was able to demonstrate the entire spectrum of LC abilities, including CD1a as their prominent hallmark molecule. We found that poison-ivy-induced skin inflammation was dominated by CD1a-dependent T H 17 cells. Using wild-type mice in the absence of CD1a, published work suggested CD8 + T cells and IFN-γ respond to urushiol 32 . However, the magnitude of inflammation appeared to be relatively mild 32 , in agreement with our observations of wild-type mice. In contrast, the response to poison ivy is strong in humans, including skin reddening, blistering, and vigorous itching, a severity well reflected in the CD1a-transgenic mouse model. Urushiol is commonly considered a pro-hapten whose catechol group is oxidized to a quinone that subsequently reacts with endogenous proteins to form an immunogen 24 . Normally, contact hypersensitivity to haptens is driven by CD8 + T cells producing IFN-γ, as seen in response to DNFB and drug hypersensitivities 24, 33 . In contrast, we demonstrate urushiol-specific, CD1a-restricted activation of CD4 + T cells that secrete IL-17. Moreover, stimulation of the immune system by DNFB was suppressed in CD1a-tg mice. As LCs are important in the suppression of hapten responses 22, 24 , CD1a-expressing LCs might be linked to dampened responses to DNFB.
In experiments with presentation by recombinant CD1a or LCs, as well as structural studies of the CD1a-urushiol complex, we found that urushiol (C15:2) was a true antigen for CD1a-restricted T cells. Although the overall structural features of the CD1a-binding cleft were generally conserved following the binding of urushiol, relative to published CD1a-antigen complexes 9 , two CD1a residues deep in the A′-pocket underwent structural rearrangements to accommodate the urushiol antigen in the binding groove. Specifically, Phe70 and Trp14 swung away to provide space for the catechol headgroup and the C15-tail of urushiol, respectively. These conformational changes had the 'knock-on' effect of altering the conformation of the CD1a antigen-binding cleft (root mean square deviation of 0.6 Å), in particular residues 146-150 (root mean square deviation of 1.3 Å), which subsequently affect the conformation of Arg73, Arg76 and Glu154, a constellation of residues known to affect the autoreactivity of a CD1a-restricted TCR 9 . Thus, a region of the urushiol antigen was accessible for direct TCR contact in the CD1a groove and, moreover, the accommodation of urushiol led to conformational changes in CD1a that might also directly affect recognition by the TCR. However, future studies will be needed to show the structure of the CD1a-urushiol-TCR ternary complex.
In addition, we found that CD1a on LCs controlled inflammation in psoriasis in both a psoriasis-like mouse model as well as human patients. Given our findings on the presentation of fatty acid and triacylglycerol, we propose that when displayed by CD1a, self lipids might represent dominant antigens in psoriasis. A study has revealed that self lipids fitting into the CD1a binding groove can change the conformation of CD1a to be recognized by specific TCRs via a mechanism of permissive autoreactivity 9 . In an integration of follow-up human studies with samples from patients, the concept of self lipids might provide important answers as to the nature of the thus-far-unknown antigens in psoriasis. The skin harbors a multitude of immune cells involved in the response to challenges. Dermal γδ T cells produce IL-17 and have been associated with psoriasis 34, 35 . We observed a comparable increase in dermal γδ T cells in CD1a-tg or wild-type mice in response to urushiol or imiquimod. In contrast, amplification of IL-17-producing αβ T cells was specific for the CD1a-tg model, which explains the predominant effect of CD1a-dependent T H 17 cells on skin inflammation. However, both T cell populations can complement each other, with γδ T cells responding early and in an innate fashion to cytokines such as IL-23, and CD1a-restricted T H 17 cells acting at a later stage in a lipid-antigen-specific manner. In patients with psoriasis, we found a particular increase in inflammatory IL-17 and IL-22 production following recognition of CD1a. Finally, our results demonstrated that blocking CD1a in vivo by antibody treatment substantially reduced skin inflammation. Thus, we propose targeting of CD1a to pave the way for future CD1a-based therapies against inflammatory skin diseases.
METHODS
Methods and any associated references are available in the online version of the paper. and crystallography, and analyzed data; M.S. generated CD1a-tg mice; J.R. and F.W. designed and supervised experiments and wrote the manuscript.
Histology and confocal microscopy. Mice were euthanized by CO 2 inhalation, and ear samples were frozen in Optimal Cutting Temperature (OCT) compound (Sakura Finetechnical Corporation). Ten µm-thick cross-sections were made and stained with hematoxylin and eosin by the Histology Core at Beth Israel Deaconess Medical Center. Images were taken using a BX63 Motorized Microscope (Olympus). For epidermal sheets, ear pinnae were treated with shaving cream (SoftSheen-Carson) and affixed to slides with the epidermis downward. The ear samples were incubated in 10 mM EDTA in PBS for 2 h at 37 °C, followed by physical removal of the dermis. Tissue was fixed in 4% paraformaldehyde (Sigma) at 25 °C for 30 min, and blocked with 10% FBS and 2% goat serum (Life Technologies) in PBS. Tissues were stained with purified anti-MHC class II and anti-CD1a, followed by staining with Alexa Fluor 647conjugated anti-rat IgG, and Alexa Fluor 488-conjugated anti-mouse IgG as secondary antibodies. Samples were mounted with ProLong Gold Antifade Mountant including DAPI (Life Technologies). Immunofluorescent images were taken using an Olympus FV1000 confocal microscope.
Expression, purification of CD1a and urushiol (C15:2) loading into CD1a.
The glycoprotein CD1a was expressed in a mammalian expression system and purified as previously described 9 . Following an endoglycosidase H (New England BioLabs) treatment, the purified CD1a was first loaded with the ganglioside GD 3 (Matreya LLC) that was dissolved in a solution containing 0.5% tyloxapol (Sigma) and 10 mM Tris buffer at pH 8.0. CD1a was first incubated with GD 3 overnight at 25 °C at a molar ratio of 1:15. The CD1a sample loaded with GD 3 was further purified using ion exchange chromatography (MonoQ 10/100 GL-GE Healthcare). Urushiol C15:2 (Chemos) was dissolved in a solution containing 10 mM Tris buffer at pH 8.0 / 0.5% tyloxapol / 50% acetone (Sigma). The GD 3 -CD1a sample was then incubated overnight with urushiol at a 1:15 molar ratio and at 25 °C in order to achieve the GD 3 displacement by urushiol. A subsequent purification step involving ion exchange chromatography (MonoQ 10/100 GL) was performed to remove the excess of urushiol C15:2, GD 3 −CD1a, and detergent.
Crystallization, structure determination and refinement. Seeds obtained from previous binary CD1a-antigen crystals 9 were used to grow crystals of the CD1a-urushiol (C15:2) binary complex in 20-25% PEG 1500/10% MMT buffer pH 5-6. The crystals were flash-frozen and data were collected at the MX2 beamline (Australian Synchrotron) to a 1.9-Å resolution. All the data were processed with the program MOSFLM and were scaled with the CCP4 suite 39 . Consistent with the mass spectrometry data, the urushiol antigen was clearly evident in the unbiased electron density maps, in addition a trace amount of an endogenous self antigen was also evident on account of the high resolution of the binary complex. An initial run of rigid body refinement was performed with the refinement program BUSTER 2.10 (ref. 40) . Iterative model improvement with COOT 41 and further refinement with BUSTER 2.10 (ref. 40) were performed. The final refinement led to an R/R-free (%) of 18.6/21.6. The quality of the structure was confirmed at the Research Collaboratory for Structural Bioinformatics Protein Data Bank Data Validation and Deposition Services website. All presentations of molecular graphics were created with the PyMOL molecular visualization system (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.).
Extraction of urushiol and mass spectrometry analysis.
In all samples, urushiol was extracted using a single phase Folch procedure 42 and analyzed using a Q-Exactive Hybrid Quadrupole-Orbitrap. Prior to urushiol extraction, crystals of CD1a-urushiol were extensively washed with the crystallization mother liquor and dissolved in Tris Buffer Saline (TBS), pH 8.0. MS was coupled to a RSLC nano HPLC (Thermo Scientific). Samples were loaded onto a nanoviper pepmap100 trap column (100 µm × 2 cm) in 2% acetonitrile/0.1% ammonium acetate at a flow rate of 15 µl/min. Analytes were separated at a flow rate of 300 nl/min on a pepmap100 C18 column (75 µm × 15 cm, Thermo Scientific) using a linear gradient of acetonitrile (2-80%). Up to 12 MS/MS spectra were acquired per cycle with maximum accumulation time of 50 ms and 100 ms for MS1 and MS2, respectively. A SCIEX QTRAP 5500 mass spectrometer was used for MRM-based detection as previously described 43 . The 5500 mass spectrometer was operated with unit quadrupole resolution and three MRM transitions were simultaneously monitored in detecting U15 315.2→149.1, 315.2→135.1, 315.2→122.1. Data analysis was performed using a combination of Analyst v1.5.2 and XCalibar 3.0 (Thermo Fisher Scientific).
Statistical analysis.
Data are presented as mean ± standard error. No statistical method was used to predetermine sample size, which instead was determined based on the results of preliminary experiments. Mice were allocated at random to experimental groups. Mouse studies were performed in a nonblinded fashion. To compare two groups, the two-tailed unpaired t test, or Mann-Whitney, or Wilcoxon test was used with or without the assumption of normality, respectively. The variance between groups was similar within each group. To compare means between more than two groups, one-way or two-way ANOVA test was performed with post multiple comparisons. P > 0.05 were considered not significant. All statistical analysis was calculated using Prism software (GraphPad).
